TAG:
pathology business
AP’s “High & Mighty” Firms Hit Tough Times
By Robert Michel | From the Volume X No. 13 – September 29, 2003 Issue
CEO SUMMARY: In the years between 1995 and 2002, public companies AmeriPath, DIANON Systems, and IMPATH built revenues and profits at a blistering pace. During this time period, these three firms captured enough market share to do almost $1 billion of anatomic pathology business in 2002. …
Non-Pathologists Altering U.S. Laboratory Industry
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: It’s an interesting contradiction. On one hand, most pathologists enthusiastically recognize the value that diagnostic testing services provide to the healthcare community. On the other hand, too often it is non-laboratorians who provide the investment capital and entrepren…
Path Trends For 2002 Show Future Direction
By Robert Michel | From the Volume IX No. 1 – January 7, 2002 Issue
CEO SUMMARY: Even as pressures to squeeze costs and consolidate within the pathology profession ease, a different set of market trends is exerting influence. Collectively, these trends portend the end of the small pathology group’s dominance of its local healthcare marketplace. It will …
THE DARK REPORT Honors Lab “Movers & Shakers”
By Robert Michel | From the Volume VIII No. 5 – April 9, 2001 Issue
CEO SUMMARY: It’s time again to recognize and honor the lab industry’s strong leaders in innovative management. These laboratory executives are implementing business strategies designed to position their lab organizations to serve the changing needs of the healthcare system. Their vis…
“Local” Anatomic Path Has Two Major Players
By Robert Michel | From the Volume VIII No. 2 – February 5, 2001 Issue
CEO SUMMARY: After a lot of money and much effort, the fledgling crop of companies wanting to consolidate and manage pathology group practices has narrowed into just two market leaders: AmeriPath and Pathology Service Associates. These two companies could not be more different in their go…
AmeriPath Will Acquire Inform DX for $44.6 Mil
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: It’s another example of consolidation in the anatomic pathology marketplace. AmeriPath, Inc.’s acquisition of Inform DX, Inc. positions the company to do as much as $350 million in revenues next year. By acquiring Inform DX, AmeriPath also gains entry into six more states…
AmeriPath & InformDX Merging To Form Largest Anatomic Pathology Firm in U.S.
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: AmeriPath and InformDX shared several common elements in their respective business strategies. Both companies believe that pathology services are best delivered at the local level and benefit from the support of a national organization. Both companies believe that physicians …
National Anatomic Pathology Companies Continue to Grow
By Robert Michel | From the Volume VII No. 13 – September 11, 2000 Issue
IT’S BOOM TIME IN ONE SEGMENT of the clinical laboratory world. The national anatomic pathology companies are posting record rates of growth and profits. The sustained and strong financial performance at DIANON Systems, Inc. and IMPATH, Inc. has not gone unnoticed…
Merger Creates “New” Pathology Competitor
By Robert Michel | From the Volume VII No. 9 – June 19, 2000 Issue
CEO SUMMARY: Pathology business consolidation and regionalization continues. Pathology Consultants of America, Inc. (PCA) and PathSOURCE, Inc. announced their intention to merge last month. The combined company will be called Inform DX, Inc. and will compete nationally for anatomic pathol…
New CEO Takes Charge At Pathology Partners
By Robert Michel | From the Volume VII No. 8 – May 30, 2000 Issue
CEO SUMMARY: Pathology Partners, Inc. got a new President and CEO this month. The company is organized to build and operate independent regional histology and cytology laboratories in support of anatomic pathologists. Its business model is different than competing pathology companies and …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized